AmCham's Healthcare Committee brings together a diverse group of member companies involved in innovative healthcare who aim to contribute to the quality, efficacy and efficiency of the Dutch healthcare system by creating an optimal environment for innovation, private initiative, and public-private collaboration. The key focus area of AmCham's Healthcare Committee is to create an optimal business climate for healthcare companies operating in the Netherlands.
Recent reports:
- In August 2025, AmCham's Healthcare Committee together with KPMG published an LSH Benchmark - 'The Future of the Sector Life Sciences in the Netherlands'. Read more here.
- In September 2022, the Healthcare Committee published the report 'Let's Connect' on the value of health solutions companies for the Netherlands.
Participating Companies
- Abbott
- Abie
- AmCham
- Amgen
- AstraZeneca
- Biogen Netherlands
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Gilead Sciences Netherlands
- GlaxoSmithKline
- Johnson & Johnson Innovative Medicine
- Lilly Nederland
- MSD
- Moderna
- Novartis Pharma
- Pfizer
- Philips
- Roche
- Sanofi
- Stryker
- UPS Healthcare
- Vertex
